Rallybio (RLYB) Expected to Announce Earnings on Thursday

Rallybio (NASDAQ:RLYB) will likely be posting its results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($1.28) per share and revenue of $0.2210 million for the quarter.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million.

Rallybio Price Performance

NASDAQ RLYB opened at $15.96 on Thursday. The business has a 50 day moving average price of $15.90 and a 200 day moving average price of $10.92. The company has a market capitalization of $84.59 million, a P/E ratio of -3.68 and a beta of -0.90. Rallybio has a 1-year low of $3.20 and a 1-year high of $17.57.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Insider Activity

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 10,200 shares of the stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $13.98 per share, for a total transaction of $142,596.00. Following the completion of the transaction, the insider directly owned 926,352 shares of the company’s stock, valued at $12,950,400.96. This trade represents a 1.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have bought a total of 302,473 shares of company stock valued at $4,229,715 over the last quarter. 10.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rallybio

A number of institutional investors and hedge funds have recently bought and sold shares of RLYB. Citadel Advisors LLC grew its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Renaissance Technologies LLC increased its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares in the last quarter. Susquehanna International Group LLP raised its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.